IW-3300 is under clinical development by Ironwood Pharmaceuticals and currently in Phase I for Endometriosis. According to GlobalData, Phase I drugs for Endometriosis have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IW-3300’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IW-3300 is under development for the treatment of visceral pain conditions such as interstitial cystitis or bladder pain syndrome (IC/BPS) and endometriosis. It acts by targeting guanylate cyclase-C. It is administered through rectal route.
Ironwood Pharmaceuticals overview
Ironwood Pharmaceuticals (Ironwood) is a healthcare company engaged in the discovery, development and commercialization of human therapeutics and innovative gastrointestinal product opportunities. The company’s pipeline products include linaclotide, and vascular or fibrotic programs. Ironwood offers its products under two brands- Linzess and Constella. The company generates a pipeline of early development candidates and discovery research programs in various therapeutic areas which include gastrointestinal (GI), central nervous system (CNS) and allergic disorders. The company’s portfolio includes CNP-104 and IW-3300. It has strategic partnerships with leading pharmaceutical companies such as AbbVie Inc, for the development and commercialization of linaclotide across the globe. The company operates in the US and Switzerland. Ironwood is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of IW-3300’s drug-specific PTSR and LoA scores, buy the report here.